GAL-101

Galimedix Therapeutics has successfully completed the single ascending dose portion of its Phase 1 trial for GAL-101, showing favorable safety and pharmacokinetic profiles in healthy volunteers.

Phase 3 clinical trials of NT-501, an encapsulated cell therapy delivering CNTF, demonstrated significant reduction in disease progression for macular telangiectasia type 2 patients, with up to 52% reduction in ellipsoid zone loss.

The dry age-related macular degeneration (AMD) therapeutic landscape is robust, with over 70 companies developing more than 80 therapies.

Galimedix Therapeutics has begun a Phase 1 clinical trial for oral GAL-101, an amyloid beta (Aβ) aggregation modulator, to assess its safety and tolerability.

Galimedix Therapeutics has commenced the eDREAM phase 2 clinical trial to evaluate GAL-101 eye drops for geographic atrophy secondary to dry age-related macular degeneration (AMD).